FDA Approves Roche's Wilserdly (Giredestrant), A Next-Generation Oral SERD, For ER-Positive, ESR1-Mutated Advanced Breast Cancer
| Study | Intervention | Patient population |
| Positive primary study readouts completed | ||
| lidERA Breast Cancer; NCT04961996 | Wilserdly versus standard endocrine therapy as adjuvant treatment14 | ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer14 |
| evERA Breast Cancer; NCT05306340 | Wilserdly plus everolimus versus standard endocrine therapy plus everolimus9 | ER-positive, HER2-negative, locally advanced or metastatic breast cancer9 |
| Primary study readouts pending | ||
| pionERA Breast Cancer; NCT06065748 | Wilserdly plus investigator's choice of a cyclin-dependent kinase (CDK)4/6 inhibitor versus fulvestrant plus an investigator's choice CDK4/6 inhibitor15 | ER-positive, HER2-negative advanced breast cancer resistant to adjuvant endocrine therapy15 |
| heredERA Breast Cancer; NCT05296798 | Wilserdly plus Phesgo® (pertuzumab, trastuzumab, and hyaluronidase subcutaneous) versus Phesgo plus optional standard endocrine therapy at investigator's discretion16 | ER-positive, HER2-positive locally advanced or metastatic breast cancer16 |
| novERA Breast Cancer; NCT07541079 | Wilserdly, evaluating adherence, tolerability, and patient-reported outcomes 17 | Patients with ER-positive, HER2-negative early-stage breast cancer who are intolerant to adjuvant aromatase inhibitor treatment17 |
| kalitERA; NCT07827573 | Wilserdly, evaluating treatment adherence, tolerability, and patient-reported outcomes18 | ER-positive, HER2-negative early-stage breast cancer18 |
About hormone receptor (HR)-positive breast cancer
Globally, the burden of breast cancer continues to grow, with 2.3 million women diagnosed and 670,000 dying from the disease every year.19 Breast cancer remains the number one cause of cancer-related deaths amongst women, and the second most common cancer type.20
HR-positive, human epidermal growth factor receptor 2-negative breast cancer accounts for approximately 70% of breast cancer cases and more than 90% are diagnosed in the early-stage.21-25 A defining feature of HR-positive breast cancer is that its tumour cells have receptors that attach to hormones like oestrogen, which can contribute to tumour growth.26
Despite treatment advances, HR-positive breast cancer remains particularly challenging to treat due to its biological complexity.2 Patients often face the risk of disease progression, treatment side effects and resistance to endocrine therapy.2,27 There is an urgent need for more effective treatments that can delay clinical progression and reduce the burden of treatment on people's lives.2,27
About Roche in breast cancer
Roche has been advancing breast cancer research for more than 30 years, and it continues to be a major focus of research and development. Our legacy includes setting and redefining standards of care with pioneering treatments such as Herceptin® (trastuzumab) and Kadcyla® (trastuzumab emtansine), and we continue to build on this with next-generation innovations such as WilserdlyTM (giredestrant), pushing the boundaries of science to address the complexities of all breast cancer subtypes.
By leveraging our dual expertise in pharmaceuticals and diagnostics, we are dedicated to providing tailored treatment approaches and improving outcomes for every patient, from early to advanced stages of the disease. Together with our partners, we are relentlessly pursuing a cure, as we strive for a future where no one dies from breast cancer.
About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.
Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.
Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.
For more information, please visit .
All trademarks used or mentioned in this release are protected by law.
References
[1] Mayer E, et al. Giredestrant plus Everolimus in Advanced Breast Cancer. NEJM. 2026; 395 (13):1285-1298.
[2] Hanker A, et al. Overcoming Endocrine Resistance in Breast Cancer. Canc Cell. 2020 Apr 13;37(4):496–513.
[3] Chandiwana D, et al. Real-world prevalence of ESR1 mutations among patients with ER-positive/ HER2-negative metastatic breast cancer after first-line treatment with endocrine therapy and/or a cyclin dependent kinase 4/6 inhibitor. Presented at: San Antonio Breast Cancer Symposium (SABCS); 2025 December 9-12; San Antonio, Texas, United States. #PS1-11-09.
[4] Wood L. A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs. 2012 Sept; 16(4):432-38.
[5] U.S. Food and Drug Administration. WILSERDLYTM (giredestrant) Prescribing Information. November 2026.
[6] Bardia A, et al. Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial. Presented at: SABCS; 2025 December 9-12; San Antonio, Texas, United States. #GS1-10.
[7] Baum M, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131-9.
[8] Thürlimann B, et al. A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer. N Engl J Med. 2005;353:2747-57.
[9] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) [Internet; cited November 2026]. Available from: .
[10] Martin M, et al. Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase 2, randomised, open-label acelERA BC study. Presented at: The European Society for Medical Oncology (ESMO) Congress; 2022 September 9-13; Paris, France. Abstract #211MO.
[11] Metcalfe C, et al. GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes. Presented at: SABCS; 2018 December 4-8; San Antonio, Texas, USA. Abstract #P5-04-07.
[12] Zhou W, et al. Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers. Cell Chem Biol. 2026 Jun 18;33(6):785-798.e11. doi: 10.1016/j.chembiol.2026.04.008. Epub 2026 May 19. PMID: 42161265.
[13] Liang J, et al. GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer. J Med Chem. 2021 Aug 26;64(16):11841-11856. doi: 10.1021/acs.jmedchem.1c00847. Epub 2021 Jul 12. PMID: 34251202.
[14] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) [Internet; cited November2026]. Available from: .
[15] ClinicalTrials.gov. A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) [Internet; cited November 2026]. Available from: .
[16] ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) [Internet; cited November2026]. Available from: .
[17] ClinicalTrials.gov. A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) [Internet; cited November 2026]. Available from: .
[18] ClinicalTrials.gov. A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment (kalitERA) [Internet; cited November 2026]. Available from: .
[19] World Health Organization. Breast Cancer [Internet; cited November 2026]. Available from: .
[20] World Health Organization. Cancer Today [Internet; cited November 2026]. Available from: .
[21] Lim E, et al. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012;26(8):688-94,696.
[22] F. Hoffmann‐La Roche Ltd. (2026) SEER Explorer All BCa by Stage. Data on file.
[23] F. Hoffmann‐La Roche Ltd. (2026) Stage Distribution. Data on file.
[24] F. Hoffmann‐La Roche Ltd. (2026) KREBS and TRM. Data on file.
[25] F. Hoffmann‐La Roche Ltd. (2026).
[26] National Cancer Institute. Hormone Therapy for Breast Cancer [Internet; cited November 2026]. Available from: .
[27] Başaran G, et al. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treat Rev. 2018 Feb;63:144-55.
Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: ...
| Tristan Schmitz Phone: +41 79 529 70 35 | Nathalie Altermatt Phone: +41 79 771 05 25 |
| Lorena Corfas Phone: +41 79 568 24 95 | Simon Goldsborough Phone: +44 797 32 72 915 |
| Karsten Kleine Phone: +41 79 461 86 83 | Kirti Pandey Phone: +41 79 398 38 53 |
| Yvette Petillon Phone: +41 79 961 92 50 | Irène Stephan Phone: +41 79 377 83 75 |
| Albert Thottiyil Phone: +41 79 775 66 12 |
Roche Investor Relations
| Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: ... | Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: ... |
| Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: ... |
Investor Relations North America
| Loren Kalm Phone: +1 650 225 3217 e-mail: ... |
Attachment
-
Media Investor Release FDA approval Wilserdly (giredestrant) English

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment